1 Min Read
June 14 (Reuters) - ABLYNX NV
* ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.